Aptadir Therapeutics S.R.L.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aptadir Therapeutics S.R.L. - overview
Established
2023
Location
Milan, -, Italy
Primary Industry
Biotechnology
About
Based in Milan, Italy and founded in 2024 by Giovanni Amabile (Co-Founder & CEO), Annalisa Di Ruscio (Co-Founder), Vittorio De Franciscis (Co-Founder), Daniel G. Tenen (Co-Founder) and Marcin Kortylewski (Co-Founder,, Aptadir Therapeutics operates as a biotechnology company focused on developing RNA-based therapeutics to support patients with diseases caused by dysregulated DNA methylation. In September 2026, Aptadir Therapeutics raised EUR 40 million in seed funding led by 4BIO Capital Partners, with participation from CE Venture Capital, XGEN Venture, Extend S. R.
L. , Angelini Ventures, Kerna Ventures, Italian Angels for Biotech, Club Degli Investitori, and CDP Venture Capital. Aptadir Therapeutics S. R.
L. offers a range of software solutions designed to improve operations across various industries. The company's offerings include a cloud-based platform that manages project management, collaboration, and workflow automation. The platform allows patients to track common pain points such as communication breakdowns, task tracking, and resource allocation.
As of 2024, the firm serves various industries such as technology, healthcare, and finance, with a specific focus on markets in North America and Europe. The company plans to utilize the September 2026 funding to support the development of its treatment research.
Current Investors
CDP Venture Capital, Evotec SE, Angelini Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
https://aptadir.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Aptadir Therapeutics S.R.L. - financials
| Fiscal Year Ended | Dec 31, 2024 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Aptadir Therapeutics S.R.L. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seed | Completed | Aptadir Therapeutics S.R.L. | - | ||||||||
| Unspecified Round | Completed | Aptadir Therapeutics S.R.L. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.